GNLX:NASDAQ
Genelux Corp
2,52 USD
arrow_downward
-0,98%(-0,025) 1D
13-окт., 16:00:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GNLX...
Open
2,53 USD
High
2,54 USD
Low
2,48 USD
Mkt. cap
113,79 млн
Avg. vol.
249,28 миң
Volume
151,88 миң
52-wk high
8,54 USD
52-wk low
2,29 USD
EPS
-0,87 USD
Beta
0,59
Shares outstanding
45,24 млн
No. of employees
26
Open
2,53 USD
High
2,54 USD
Low
2,48 USD
Mkt. cap
113,79 млн
Avg. vol.
249,28 миң
Volume
151,88 миң
52-wk high
8,54 USD
52-wk low
2,29 USD
EPS
-0,87 USD
Beta
0,59
Shares outstanding
45,24 млн
No. of employees
26
News stories
From web sources and news partners
https://www.dars.gov.et/
·
1 ай мурун
GNLX Q2 2026 Earnings: Wider-than-Expected Loss Reflects Continued Clinical Investment - Consensus Miss Rate
Profile
Genelux Corporation is a publicly traded late clinical-stage company developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
About Genelux Corp
CEO-
Employees26
Founded2001
HeadquartersУэстлейк Виллидж, Калифорния, Америка Кошмо Штаттары
Sector-
Websitegenelux.com